Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice

Abstract

Objective

To assess treatment patterns of Ixekizumab (IXE) and evaluate the speed of onset and long-term clinical and quality-of-life outcomes among a subset of patients who switched from adalimumab (ADA) and secukinumab (SEC) to IXE in a real-world setting.

Method

A retrospective chart review study was conducted at a single US dermatology referral center.

Result

153 patients were included in the study, 69.3% of patients were biologic-experienced. ADA was the most commonly used biologic prior to IXE initiation. 66.7% of patients remained on IXE at the study end. 47.7% of patients received concomitant methotrexate, and usage decreased consistently after 1 month. IXE treatment duration was longer among patients who were early responders (achieved sPGA (0,1) at 1 month) vs. non-early responders. 69.4% and 43.3% of patients who switched from ADA and SEC to IXE achieved sPGA (0,1) by week 4, respectively.

Conclusion

Patients who switched to IXE, specifically from ADA or SEC, had rapid treatment response as well as desirable long-term outcomes. IXE persistence was longer among early responders than non-early responders. Concomitant usage of methotrexate prior to switching to IXE and as a concomitant bridging treatment was reduced after IXE initiation while the proportion of patients achieving treatment targets remained high.

Keywords:

• Ixekizumab
• psoriasis
• real-world
• treatment pattern

Acknowledgment

We thank Alyssa Garrelts, Clinical Research Scientist, for several thoughtful comments and insights for this manuscript.

Disclosure statement

C. Leonardi has received honoraria from Eli Lilly for the following: Advisory Board, Speaker, and Consultant. R. Tao, S. Setayeshgar, S. Wang are employees of ICON plc., a company contracted by Eli Lilly to conduct this study. R. Burge, B. Zhu, and W.N. Malatestinic are employees of Eli Lilly.

Data availability statement

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Additional information

Funding

The study was funded by Eli Lilly and Company.